メシル酸レンバチニB

メシル酸レンバチニB 化学構造式
857890-39-2
CAS番号.
857890-39-2
化学名:
メシル酸レンバチニB
别名:
メシル酸レンバチニB;レンバチニブメシル酸塩;レンバチニブメシル酸塩 (JAN)
英語名:
lenvatinib Mesylate
英語别名:
Lenvatinib mesilate;4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate;CAT#A863437;E7080 Mesylate;envatinib MesyL;Lenvatinib Meylate;Levatinib mesylate;Lenvatinib Mesylat;levitinib mesylate;E7080;E-7080;E 7080
CBNumber:
CB42651170
化学式:
C22H23ClN4O7S
分子量:
522.95862
MOL File:
857890-39-2.mol
MSDS File:
SDS

メシル酸レンバチニB 物理性質

融点 :
>220°C (dec.)
貯蔵温度 :
-20°C Freezer
溶解性:
DMSO(微量)、メタノール(微量)
外見 :
個体
色:
ホワイトからオフホワイト
InChIKey:
HWLFIUUAYLEFCT-UHFFFAOYSA-N
SMILES:
O=C(N)C1C=C2C(N=CC=C2OC2C=C(Cl)C(NC(=O)NC3CC3)=CC=2)=CC=1OC.CS(=O)(O)=O
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
絵表示(GHS) GHS hazard pictograms
注意喚起語 警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H302 飲み込むと有害 急性毒性、経口 4 警告 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 皮膚刺激 皮膚腐食性/刺激性 2 警告 GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 強い眼刺激 眼に対する重篤な損傷性/眼刺激 性 2A 警告 GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 呼吸器への刺激のおそれ 特定標的臓器毒性、単回暴露; 気道刺激性 3 警告 GHS hazard pictograms
注意書き
P261 粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。
P305+P351+P338 眼に入った場合:水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

メシル酸レンバチニB 価格 もっと(5)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01COBQV-5519 メシル酸レンバチニb
Lenvatinib mesylate
857890-39-2 250mg ¥39600 2018-12-26 購入
富士フイルム和光純薬株式会社(wako) W01COBQV-5519 メシル酸レンバチニb
Lenvatinib mesylate
857890-39-2 1g ¥97200 2018-12-26 購入
Sigma-Aldrich Japan SML3017 ≥98% (HPLC)
Lenvatinib mesylate ≥98% (HPLC)
857890-39-2 10MG ¥14800 2024-03-01 購入
Sigma-Aldrich Japan SML3017 ≥98% (HPLC)
Lenvatinib mesylate ≥98% (HPLC)
857890-39-2 50MG ¥59200 2024-03-01 購入
富士フイルム和光純薬株式会社(wako) W01COBQV-5519 メシル酸レンバチニb
Lenvatinib mesylate
857890-39-2 5g ¥291600 2018-12-26 購入

メシル酸レンバチニB 化学特性,用途語,生産方法

効能

抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬

商品名

レンビマ (エーザイ)

説明

Lenvatinib mesylate (lenvatinib) is an oral targeted therapy medicine known as a receptor‐type tyrosine kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily), which was developed at Eisai in 2015. It was approved by the FDA in 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent, metastatic, or progressive and did not respond to radioactive iodine treatment. In May 2016, the FDA approved the drug as a combination therapy with everolimus for the treatment of advanced renal cell carcinoma. Because VEGF (and fibroblast growth factor receptors, known as FGFRs) are thought to play a role in cardiovascular signaling pathways, VEGF2R and FGFR inhibition are thought to be the mechanisms behind the primary side effect of lenvatinib mesylate, which is hypertension.

使用

Lenvatinib mesylate is used in cancer:(1) Endometrial carcinoma that is advanced and got worse after other systemic therapies. It is used with pembrolizumab in patients whose cancer is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) and cannot be treated with surgery or radiation therapy.(2) Hepatocellular carcinoma (a type of liver cancer). It is used as the first treatment in patients whose cancer cannot be removed by surgery.(3) Renal cell carcinoma (a type of kidney cancer) that is advanced(4)Thyroid cancer in certain patients whose cancer got worse, came back, or has spread to other parts of the body and did not respond to treatment with radioactive iodine.(5) Lenvatinib Mesylate is used in preparation of anti-human CTLA4xPD-1 bispecific antibodies for diagnosis, prevention and treatment of tumor or anemia.
Lenvatinib mesylate is also being studied in the treatment of other types of cancer.

定義

ChEBI: Lenvatinib mesylate is a methanesulfonate salt obtained by reaction of lenvatinib with one molar equivalent of methanesulfonic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine. It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast growth factor receptor antagonist, an orphan drug, a vascular endothelial growth factor receptor antagonist and an antineoplastic agent. It contains a lenvatinib(1+).

作用機序

Lenvatinib mesylate works by blocking proteins that signal cancer cells to multiply. It also blocks proteins that signal the formation of new blood vessels that are needed to support tumor growth. Blocking these signals keeps cancer cells from growing.

メシル酸レンバチニB 上流と下流の製品情報

原材料

準備製品


メシル酸レンバチニB 生産企業

Global( 355)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Zison Pharmaceutical (Shandong) Co., Ltd.
+86-0086-531-88259693 +86-18660188356
maguanglei@zisonpharm.com China 53 58
Beijing Mesochem Technology Co.,Ltd
+8613651027935
rachel@mesochem.com China 191 58
Hebei Duling International Trade Co. LTD
+8618032673083
sales05@hbduling.cn China 15755 58
Jewim Pharmaceutical (Shandong) Co., Ltd.
+86-15552509998 +86-15621883869
liutf@jewim.com.cn China 251 58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.
+86-0531-69954981 +8615666777973
dwyane.wang@boyuanpharm.com China 211 58
shan dong Fengjin Pharmaceutical company
+8615066764791
liangfulin@fengjin-pharma.com China 8 58
Hebei Guanlang Biotechnology Co,.LTD
+8619930503252
daisy@crovellbio.com China 5966 58
Sinoway Industrial co., ltd.
0592-5800732; +8613806035118
xie@china-sinoway.com China 990 58
shandong perfect biotechnology co.ltd
+86-53169958659; +8618596095638
sales@sdperfect.com China 294 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971 +86-17331933971
deasea125996@gmail.com China 2504 58

857890-39-2(メシル酸レンバチニB)キーワード:


  • 857890-39-2
  • lenvatinib Methanesulfonate
  • E7080 Mesylate
  • 4-[3chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate
  • lenvatinib Mesylate
  • CAT#A863437
  • Lenvatinib Mesylate,Amadis Chemical offer CAS#857890-39-2
  • E7080;E-7080;E 7080
  • maltitol E:candyli(at)speedgainpharma(dot)com
  • LENVATINIB MESYLATE (E7080 MESYLATE)
  • 4-[3-chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide mesylate
  • lenvatinib Mesylate (E7080)
  • 6-Quinolinecarboxamide,4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-,monomethanesulfonate
  • envatinib MesyL
  • lenvatinib Mesylate USP/EP/BP
  • lenvatinib Mesylater
  • 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide methanesulfonate
  • Lenvatinib mesylateQ: What is Lenvatinib mesylate Q: What is the CAS Number of Lenvatinib mesylate
  • 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate
  • Lenvatinib mesilate
  • Levaritinib mesylate
  • Piperazine,5-(methylsulfonyl)-
  • Lenvatinib Meylate
  • Levatinib mesylate
  • Lenvatinib Mesylat
  • Lenvatinib mesylaye
  • Levantinib mesylate
  • Lenvatinib Mesylate (Form C and MIBK Solvate)
  • 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide mesylate
  • levitinib mesylate
  • メシル酸レンバチニB
  • レンバチニブメシル酸塩
  • レンバチニブメシル酸塩 (JAN)
Copyright 2017 © ChemicalBook. All rights reserved